Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to a combination of two distinct types of dendritic cells used together, typically in the context of cell therapy or immunotherapy research. Myeloid dendritic cells (mDCs) are professional antigen-presenting cells derived from myeloid precursors, known for their ability to stimulate T-cell responses and bridge innate and adaptive immunity. Plasmacytoid dendritic cells (pDCs) are a rare subset that secrete large amounts of type I interferons in response to viral infections and also play roles in immune regulation, autoimmunity, and cancer microenvironments[1][3][4]. The combination may be explored for therapeutic purposes such as cancer immunotherapy or modulation of immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on myeloid dendritic cells + plasmacytoid dendritic cells.